TBC1D22A

Across TCGA pan-cancer cohorts, TBC1D22A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TBC1D22A data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher TBC1D22A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBC1D22A expression acts as an unfavorable survival marker.

SCLC, KICH, and UCEC are the cancer types where TBC1D22A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.178	0.714	<.001	36	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TBC1D22A–SCLC (OS)

Open the SCLC breakdown →